GlassScriptPhysician profile
Yvette Mcfarlane
NPI 1760840649
$3,060.12
in general payments reported to CMS, 2019-2025
23 companies · $623 in 2025
The $623 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $467 · 2022: $661 · 2023: $789 · 2024: $521 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $644.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $472.95 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $308.51 | 2021-2025 | Evenity, Prolia, Repatha |
| Biosense Webster, INC. | $247.13 | 2022-2023 | Carto 3 |
| Medtronic, INC. | $200.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.00 | 2021-2023 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $166.32 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $138.55 | 2021-2025 | |
| Astellas Pharma US INC | $136.65 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $74.73 | 2022-2024 | |
| Mannkind Corporation | $67.71 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $65.97 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $64.81 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $47.94 | 2024-2025 | |
| Pfizer INC. | $44.36 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.15 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $40.45 | 2023-2024 | Arexvy |
| Merck Sharp & Dohme LLC | $32.91 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Viiv Healthcare Company | $19.13 | 2024 | Apretude |
| Kowa Pharmaceuticals America, INC. | $18.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.31 | 2023 | Breztri |
| Halozyme INC | $14.46 | 2023 | |
| Dexcom, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.